Biovet JSC (LTS:0III) Notes Receivable: лв0.00 Mil (As of Dec. 2016)


What is Biovet JSC Notes Receivable?

Biovet JSC LTS:0III Notes Receivable is лв0.00 Mil as of Dec. 2016. The stock has 1 warning sign investors should review.

Biovet JSC's Notes Receivable for the quarter that ended in Dec. 2016 was лв0.00 Mil.

Biovet JSC Notes Receivable Historical Data

* Premium members only.

The historical data trend for Biovet JSC's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biovet JSC Notes Receivable Chart

Biovet JSC Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Biovet JSC Quarterly Data
Dec09 Dec10 Dec11 Dec12 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biovet JSC Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of лв0.00 Mil mean?
Biovet JSC (LTS:0III) has a Notes Receivable of лв0.00 Mil as of Dec. 2016. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biovet JSC and its competitors.
Is Biovet JSC's Notes Receivable too high?
Biovet JSC's current Notes Receivable is лв0.00 Mil.
How does Biovet JSC's Notes Receivable compare to ADMP and AGRX?
Biovet JSC's Notes Receivable of лв0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biovet JSC and its competitors. Biovet JSC's current Notes Receivable is лв0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current Notes Receivable of лв0.00 Mil. The current Notes Receivable is лв0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current Notes Receivable is лв0.00 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biovet JSC Business Description

Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.